Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data
Close

GSK plc (GS71)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
16.260 -0.020    -0.12%
03/02 - Closed. Currency in EUR ( Disclaimer )
  • Volume: 37,994
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 16.020 - 16.340
Type:  Equity
Market:  Germany
ISIN:  GB00BN7SWP63 
WKN:  A3DMB5
GSK plc 16.260 -0.020 -0.12%

GS71 Financial Summary

 
See below for an overview of the Glaxo financial reports. To explore the data further, select a tab to navigate onto a specific report page. Choose to view either annual or quarterly report data.

GSK plc reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was GBP 7,829 million compared to GBP 6,627 million a year ago. Net income was GBP 10,315 million compared to GBP 1,168 million a year ago. Basic earnings per share from continuing operations was GBP 0.188 compared to GBP 0.219 a year ago. Diluted earnings per share from continuing operations was GBP 0.186 compared to GBP 0.216 a year ago. Basic earnings per share was GBP 2.559 compared to GBP 0.292 a year ago. Diluted earnings per share was GBP 2.523 compared to GBP 0.288 a year ago.For the nine months, sales was GBP 21,948 million compared to GBP 17,620 million a year ago. Net income was GBP 12,955 million compared to GBP 3,636 million a year ago. Basic earnings per share from continuing operations was GBP 0.736 compared to GBP 0.722 a year ago. Diluted earnings per share from continuing operations was GBP 0.725 compared to GBP 0.714 a year ago. Basic earnings per share was GBP 3.22 compared to GBP 0.908 a year ago. Diluted earnings per share was GBP 3.173 compared to GBP 0.898 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

GS71 Income Statement

Gross margin TTM 67.42%
Operating margin TTM 24.19%
Net Profit margin TTM 35.65%
Return on Investment TTM 19.75%
 Total Revenue  Net Income
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Total Revenue 7829 6929 7190
Gross Profit 5443 4784 4500
Operating Income 2361 1709 1708
Net Income 10315 838 1802

GS71 Balance Sheet

Quick Ratio MRQ 0.65
Current Ratio MRQ 0.91
LT Debt to Equity MRQ 160.74%
Total Debt to Equity MRQ 198.03%
 Total Assets  Total Liabilities
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Total Assets 60313 89045 89689 79103
Total Liabilities 51597 66405 67057 57761
Total Equity 8716 22640 22632 21342

GS71 Cash Flow Statement

Cash Flow/Share TTM 2.29
Revenue/Share TTM 9.5
Operating Cash Flow  6.30%
 Cash  Net Change in Cash
Period Ending: Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 1321 2542
Cash From Investing Activities -4094 -3593
Cash From Financing Activities -1326 7973
Net Change in Cash -4076 6934
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

GSK Comments

Write your thoughts about GSK plc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
John Ford
John Ford Jan 24, 2023 15:53
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
All export earners today are going south
Reply
0 0
Report
Dan Morris
Dan Morris Dec 07, 2022 13:23
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lovely little boost from the Zantec case today. Let's hope the shares kick onwards from here
Reply
2 0
Report
איציק צארלי
איציק צארלי Nov 28, 2022 16:10
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
ITH stock
Reply
1 0
Report
Anon Anon
Anon Anon Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bought back all the gsk that I sold back in May. It's a no brainer at this price
Reply
6 0
Report
Anon Anon
Anon Anon Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buying GSK is like investing in a junk bond. One need to buy when the yield is high
Reply
0 0
Report
Mike Bamber
Mike Bamber Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
. Well, yield is OK as long as it's not offset by value destruction through capital loss. In GSKs case as long as Walmsley is at the helm you can guarantee value destruction. She couldn't develop a blockbuster drug or vaccine if her life depended on it. Pascal Sorrel at Astra Zenrcca must be laughing his head off at this train crash of a CEO
Reply
1 0
Report
Anon Anon
Anon Anon Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
You are right. Also the price has been range bound for a decade and we are now near to the lower bound. I've heard similar comments to you nearly ever year when it's price is underperforming
Reply
0 0
Report
Mike Bamber
Mike Bamber Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I wish the institutional shareholders would wake up and do something about the management team. Surely with such an abysmal performance over so long GSK must be a takeover target?
Reply
0 0
Report
Anon Anon
Anon Anon Nov 11, 2022 16:51
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
I'm only interested in swing trading this counter. If the price doesn't move I'll just collect dividends while waiting for it to bounce. The spinoff of Haleon is a good move as in this day and age companies need to be pure play to get ahead of competition. Consumer healthcare business was a distraction to their management.
Reply
0 0
Report
John Hamilton
John Hamilton Nov 11, 2022 12:15
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
new management required
Reply
2 0
Report
John Williams
John Williams Sep 08, 2022 14:10
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Bloodbath coming
Reply
0 3
Report
Ozkan Gokmenoglu
Ozkan Gokmenoglu Sep 08, 2022 14:10
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Hi John, it will be worsth ?
Reply
0 0
Report
Alun Benjamin
Alun Benjamin Sep 08, 2022 14:10
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
When will this carnage start, exacty (02/11/22)
Reply
0 0
Report
Jenny Gough
Jenny Gough Aug 11, 2022 11:43
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Should have taken the Unilever offer...
Reply
9 0
Report
Mark Olive
magicpiano Aug 11, 2022 11:43
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
It was madness not to.
Reply
2 0
Report
Mike Bamber
Mike Bamber Jul 18, 2022 16:06
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Demerger yet another damp squib in a long line of failures by Walmsley. She is unprecedented in her ability to talk the talk but to not walk the walk!
Reply
9 2
Report
Anon Anon
Anon Anon Jan 17, 2022 11:43
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This may go up further but I've started to take some profit as precaution. I suspect ulvr may not revise their offer after its sp tanking showing clear sentiments from shareholding to reject this move
Reply
2 2
Report
Anon Anon
Anon Anon Dec 09, 2021 8:46
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Moving closer to my 1800 tgt (posted on March 30). This stock pays very generous dividend I have to say
Reply
6 4
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email